APOC3 inhibition: The strongest case yet for triglyceride targeting.

Shapiro MD, Slipczuk L

Bridging the inflammation gap by IL-6 inhibition.

Shapiro MD

Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial.

Ashburn NP, Snavely AC, Ehrig MR, Shapiro MD, Herrington DM, Reboussin DM, Gesell SB, Mahler SA

Impact of a Meds-to-Beds PCSK9i Initiation Program on LDL-C in Patients Undergoing ASCVD Revascularization.

Lorenzatti D, Greenberg GS, Filtz A, Scotti A, Jaspan VN, Park CM, Kalich B, Jones LK, Kathe N, Di Palo KE, Browne C, Lipsitz E, Forest SJ, Latib A, Garcia MJ, Rodriguez CJ, Shapiro MD, Gulati M, Slipczuk L

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.

Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A

Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension.

Kazibwe R, Jehopio J, Schaich CL, Rikhi R, Mirzai S, Chevli PA, Namutebi JH, Chebrolu S, O'Connor S, Yeboah J, Shapiro MD

First presentation of atherosclerotic cardiovascular disease in previously healthy individuals: The multi-ethnic study of atherosclerosis.

Kermanshahchi J, Kao AS, Ellberg CC, Duran E, Criqui MH, Shapiro MD, Bhatia HS

T Cells, Triglycerides, and the Immune Roots of Residual Cardiovascular Risk.

Shapiro MD

ASPC president's page: Preparing the next generation of leaders in preventive cardiology.

Shapiro MD

The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.

Lala A, Beavers C, Blumer V, Brewer L, De Oliveira-Gomes D, Dunbar S, Every H, Ferraro R, Ky B, Januzzi J, Marvel F, Mentz R, Michos E, Narula J, Nasir K, Natarajan P, Peterson LA, Rodriguez F, Shapiro MD, Skowronski J, Starling RC, Taub P, Tedford RJ, Youmans Q, Zieroth S, Gulati M